Stamaril is a live attenuated vaccine used to protect against yellow fever, a serious viral disease transmitted by infected mosquitoes and endemic in parts of Africa and South America. The vaccine is produced by Sanofi Pasteur and contains a weakened strain of the yellow fever virus (17D strain), which stimulates the immune system to produce long-lasting protective antibodies.
Key Information:
-
Indication: Prevention of yellow fever in individuals aged 9 months and older who are traveling to or living in endemic areas, or as required by international travel regulations (IHR).
-
Administration: Single subcutaneous or intramuscular injection (0.5 ml).
-
Immunity Onset: Protective immunity typically develops within 10 days after vaccination.
-
Duration of Protection: A single dose provides lifelong protection in most individuals (as per WHO guidelines).
-
Vaccination Certificate: Issued and valid 10 days after vaccination, required for entry into certain countries (International Certificate of Vaccination or Prophylaxis – ICVP).
-
Contraindications: Severe allergy to egg proteins, immunosuppression, pregnancy (relative), infants under 9 months (except in outbreak situations), and certain chronic conditions.
Important:
Stamaril must be administered by a certified yellow fever vaccination center, and proper documentation must be provided to meet international travel requirements.
